



# Pharmacogenetic PGx Report

Assay Ordered	Pain Panel
Patient Name	Anonymous
Patient ID#	00000001
DOB	Unknown
Gender	Female
Sample Collection Date	N/A
Version	1.0

**The Scylex Inc. Pharmacogenetic (PGx) Report** is an analysis of the patient's DNA to identify relevant genetic variants to help inform medication efficacy, safety and dosing. Interpretation of the identified gene variants are done by **Scylex Inc.** and are based on the Clinical Pharmacogenetics Implementation Consortium (CPIC)\* focusing on immediately actionable clinical recommendations regarding safer and/or more effective medications and dosing for the patient. If applicable, the Medication Report section pairs genetic variant data with the most current FDA-approved drug labels\*\*. This report is meant as an adjunct to your health care provider's recommended treatments. The interpretation of this report should be done in consultation with a qualified healthcare professional. The information provided in this report serves as a valuable tool to support personalized medicine and facilitate informed decision-making regarding medication selection and dosing. Any additional medications listed that have no FDA approved PGx guidance are optional and only provided for educational purposes.

## Key Benefits of your Scylex PGx Report:

- **Enhanced medication selection:** The test results will help healthcare professionals identify medications that are more likely to be effective and/or safe for you, based on your genetic profile.
- **Minimized adverse effects:** By considering your genetic variations, healthcare professionals can potentially reduce the risk of adverse drug reactions or unwanted side effects.
- **Optimized dosing:** Pharmacogenetic testing can aid in determining the appropriate dosage of medications, taking into consideration your genetic factors and individual characteristics. Thereby limiting the common trial and error process of finding the right dosage.
- **Improved treatment outcomes:** Personalized medication strategies guided by pharmacogenetic information may enhance the effectiveness of treatment and improve health outcomes.

\* <https://cpicpgx.org>

\*\* <https://www.fda.gov/medical-devices/precision-medicine/fda-recognition-public-human-genetic-variant-databases>

## Sections

- I. Drug Recommendation Summary
- II. Dosing Recommendation Summary
- III. Genotype Summary and Implications
- IV. Disclaimers



### Section 1 Drug Recommendation Summary<sup>1</sup>

Drug	Pharmacogenetic Test	Test Result	Recommendation
Drug A	Test A	Result A	Recommendation A
Drug B	Test B	Result B	Recommendation B

<sup>1</sup> This section provides a summary of drug recommendations based on the patient's pharmacogenetic test results. For more detailed information, please refer to the full report.



## Section II: Dining Recommendation Summary<sup>1</sup>

No.	Title	Recommendation
100	100	<p>The Board is recommended to take the following action on the application for the position of Director of the Department of Health and Human Services:</p> <ul style="list-style-type: none"> <li>1. Approve the application.</li> <li>2. Approve the proposed salary.</li> </ul> <p>It is further recommended that the Board:</p> <ul style="list-style-type: none"> <li>a. Approve the application.</li> <li>b. Approve the proposed salary of \$100,000 per annum, plus the cost of health insurance, plus the cost of dental insurance, plus the cost of life insurance, plus the cost of pension, plus the cost of other benefits.</li> </ul> <p>The Board is recommended to take the following action on the application:</p>
100	100	<p>The Board is recommended to take the following action on the application for the position of Director of the Department of Health and Human Services:</p> <ul style="list-style-type: none"> <li>1. Approve the application.</li> <li>2. Approve the proposed salary.</li> </ul> <p>It is further recommended that the Board:</p> <ul style="list-style-type: none"> <li>a. Approve the application.</li> <li>b. Approve the proposed salary of \$100,000 per annum, plus the cost of health insurance, plus the cost of dental insurance, plus the cost of life insurance, plus the cost of pension, plus the cost of other benefits.</li> </ul> <p>The Board is recommended to take the following action on the application:</p>

<sup>1</sup> This summary recommendation does not constitute an offer of employment. The actual offer of employment will be made by the Department of Health and Human Services. For more information, please contact the Department of Health and Human Services.





### QUESTION

The following information relates to the company's operations for the year ended 31st December 2020:

Revenue: 1000000

Cost of sales: 600000

Administrative expenses: 100000

Depreciation: 50000

Interest on bank loan: 20000

Dividend received: 10000

Profit before tax: 230000

Tax expense: 46000

Profit after tax: 184000

### REQUIRED

Calculate the company's operating profit for the year ended 31st December 2020.

Answer:	184000
Explanation:	The profit after tax is 184000. This is the operating profit for the year ended 31st December 2020.

### QUESTION

The following information relates to the company's operations for the year ended 31st December 2020:

Revenue: 1000000

Cost of sales: 600000

Administrative expenses: 100000

Depreciation: 50000

Interest on bank loan: 20000

Dividend received: 10000

Profit before tax: 230000

Tax expense: 46000

Profit after tax: 184000

### REQUIRED

Calculate the company's operating profit for the year ended 31st December 2020.

Answer:	184000
Explanation:	The profit after tax is 184000. This is the operating profit for the year ended 31st December 2020.

### QUESTION

The following information relates to the company's operations for the year ended 31st December 2020:

Revenue: 1000000

Cost of sales: 600000

Administrative expenses: 100000

Depreciation: 50000

Interest on bank loan: 20000

Dividend received: 10000

Profit before tax: 230000

Tax expense: 46000

Profit after tax: 184000